Application of sulforaphane and / or sulforaphane clathrate compound in preparation of medicine for treating and / or relieving irritable bowel syndrome and visceral hypersensitivity and regulating intestinal motility or intestinal barrier

By using sulforaphane and cyclodextrin derivative inclusions, the problem of poor effectiveness of existing drugs in the treatment of irritable bowel syndrome and functional enteropathy has been solved, and more effective symptom relief and intestinal function have been achieved. Improved, improving the stability and bioavailability of the drug.

CN118924730APending Publication Date: 2024-11-12PIONEER HERB IND CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411011565.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-26
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing drugs for the treatment of irritable bowel syndrome and functional enteropathy are poor, and their mechanism of action is unclear, making it difficult to effectively alleviate the complex and diverse clinical symptoms.

Method used

Sulvolaphane and its inclusions, especially those combined with cyclodextrin and its derivatives, are used to prepare the treatment of irritable bowel syndrome, visceral hypersensitivity, intestinal dynamics abnormalities and intestinal intestinal Drugs with damaged tract barriers enhance therapeutic effects by improving the stability and bioavailability of sulforaphane.

Benefits of technology

Significantly improves the symptoms of irritable bowel syndrome, reduces visceral hypersensitivity reactions, regulates intestinal motility, improves intestinal barriers, improves the half-life and bioavailability of drugs, reduces side effects, and provides safer and more effective treatment options.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118924730A_ABST
    Figure CN118924730A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medicines, and provides application of sulforaphane and / or a sulforaphane inclusion compound in preparation of medicines for treating and / or relieving irritable bowel syndrome and visceral hypersensitivity and regulating intestinal motility or intestinal barrier. The sulforaphane provided by the invention can effectively reduce visceral hypersensitivity, regulate intestinal motility and improve intestinal barrier in preparation of medicines for treating functional bowel diseases such as irritable bowel syndrome, especially in preparation of medicines for treating visceral hypersensitivity, abnormal intestinal motility and damaged intestinal barrier function, so that the sulforaphane can be used for treating functional bowel diseases such as irritable bowel syndrome and the like. The traditional Chinese medicine composition has the effect of relieving and treating the irritable bowel syndrome. According to the sulforaphane inclusion compound, the stability and bioavailability of the sulforaphane are further improved, the half-life period of the medicine is prolonged, the treatment effect is enhanced, and the potential of the sulforaphane in clinical application is expanded.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of pharmaceutical technology, and in particular to the use of sulforaphane and sulforaphane inclusion complexes in the preparation of drugs for treating and / or relieving irritable bowel syndrome, visceral hypersensitivity reactions, and regulating intestinal motility or intestinal barrier. Background Art

[0002] Functional Gastrointestinal Disorders (FGIDs) are a class of diseases characterized by gastrointestinal dysfunction, without organic, biochemical or anatomical lesions. Common clinical FGIDs include irritable bowel syndrome (IBS), functional constipation, functional diarrhea and functional abdominal pain syndrome, which not only burden the patient's physical health, but also have a profound impact on their psychological and social life.

[0003] IBS is one of the most common functional bowel diseases with obvious symptoms. About 5%-10% of the world's population is affected by it, which brings tremendous pressure to national health and social economy. The main symptoms of IBS include recurrent abdominal pain and changes in bowel habits or forms. Its specific pathogenesis is not yet fully understood, and it is generally believed to be related to multiple factors such as intestinal hypersensitivity, intestinal motility abnormalities, intestinal barrier damage, intestinal infection, and intestinal flora imbalance. The challenge in treating IBS lies in how to effectively alleviate these complex and diverse clinical symptoms.

[0004] At present, the western medicine strategy for treating IBS mainly includes the use of laxatives / antidiarrheals, antispasmodics and antibiotics, supplemented by probiotics and dietary adjustments, aiming to relieve symptoms and reduce the impact on daily life. Traditional Chinese medicine treatment also uses a variety of compound medicines, but their effects and mechanisms of action are still unclear. CN113499402A discloses a Chinese medicine composition for treating IBS. Although a variety of ingredients are listed, the specific role of each ingredient and its main contribution in the combination are not clear. Sulforaphane, as a sulfur-containing compound extracted from cruciferous plants, has attracted much attention due to its anti-inflammatory and antioxidant biological activities. Summary of the invention

[0005] In view of the above problems, the purpose of the present invention is to develop a drug that can effectively relieve multiple symptoms of functional bowel disease. The present invention provides a use of sulforaphane and / or sulforaphane inclusion complex in the preparation of a drug for treating and / or relieving irritable bowel syndrome, visceral hypersensitivity, and regulating intestinal motility or intestinal barrier. The sulforaphane of the present invention is used to prepare a drug for treating and / or relieving irritable bowel syndrome, which has the effect of relieving and treating irritable bowel syndrome, and provides an effective treatment for irritable bowel syndrome; in particular, the use of sulforaphane in the preparation of drugs for visceral hypersensitivity, abnormal intestinal motility and impaired intestinal barrier function can effectively reduce visceral hypersensitivity, regulate intestinal motility, and improve intestinal barrier.

[0006] In order to achieve the above objectives, the present invention provides, in a first aspect, a use of sulforaphane in the preparation of a drug for treating and / or alleviating irritable bowel syndrome.

[0007] A second aspect of the present invention provides a use of a sulforaphane inclusion complex in the preparation of a drug for treating and / or alleviating irritable bowel syndrome, wherein the sulforaphane inclusion complex comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives.

[0008] A third aspect of the present invention provides a use of sulforaphane and / or a sulforaphane inclusion complex in the preparation of a drug for treating and / or alleviating visceral hypersensitivity, wherein the sulforaphane inclusion complex comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives.

[0009] A fourth aspect of the present invention provides a use of sulforaphane and / or a sulforaphane inclusion complex in the preparation of a drug for regulating intestinal motility, wherein the sulforaphane inclusion complex comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives.

[0010] A fifth aspect of the present invention provides a use of sulforaphane and / or a sulforaphane inclusion complex in the preparation of a drug for improving intestinal barrier function. The sulforaphane inclusion complex comprises sulforaphane and an inclusion material, and the inclusion material is selected from cyclodextrin and its derivatives.

[0011] Through the above technical scheme, the sulforaphane of the present invention has the effect of relieving and treating irritable bowel syndrome in the preparation of drugs for treating functional bowel diseases such as irritable bowel syndrome, and provides an effective treatment for irritable bowel syndrome; in particular, in the preparation of drugs for visceral hypersensitivity, intestinal motility disorders and impaired intestinal barrier function, it can effectively reduce visceral hypersensitivity, regulate intestinal motility, and improve intestinal barrier. Further, the sulforaphane inclusion compound of the present invention can improve the stability of sulforaphane and increase the bioavailability of sulforaphane, increase the half-life of the drug, enhance the therapeutic effect, further expand the potential of sulforaphane in clinical applications, and has higher bioavailability, and is expected to reduce the side effects of the drug by reducing the dosage and frequency of drug use, achieve better therapeutic effects, and provide a safer and more effective treatment option for patients with intestinal dysfunction, which is of great significance for improving the quality of life of patients. Through research on mouse models, it is shown that the sulforaphane and sulforaphane inclusion compound of the present invention have significant improvement effects in reducing visceral hypersensitivity, regulating intestinal motility and improving intestinal barrier. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 is a schematic diagram of the formation process of the sulforaphane inclusion complex of the present invention;

[0013] Figure 2 Schematic diagram of the establishment of the PI-IBS mouse model and the dosing regimen in the embodiment of the present invention;

[0014] Figure 3 This is a HE staining image of mouse colon tissue in an embodiment of the present invention;

[0015] Figure 4 is a bar graph of abdominal withdrawal reflex scores after modeling in an embodiment of the present invention;

[0016] Figure 5 is a bar graph of abdominal withdrawal reflex scores of drug intervention in an embodiment of the present invention;

[0017] Figure 6 is a box plot of detecting mouse intestinal motility by carmine in an embodiment of the present invention;

[0018] Figure 7 is a box plot of mouse intestinal permeability detected by FITC-D4000 marker in an embodiment of the present invention;

[0019] Figure 8 is a dot plot of the stability of sulforaphane at 37° C. in an embodiment of the present invention;

[0020] Fig. 9 It is a drug concentration-time curve diagram in an embodiment of the present invention. DETAILED DESCRIPTION

[0021] The endpoints and any values ​​of the ranges disclosed in this article are not limited to the precise ranges or values, and these ranges or values ​​should be understood to include values ​​close to these ranges or values. For numerical ranges, the endpoint values ​​of each range, the endpoint values ​​of each range and the individual point values, and the individual point values ​​can be combined with each other to obtain one or more new numerical ranges, which should be considered as specifically disclosed in this article.

[0022] When the attached figures are bar graphs and / or box plots, the figures are marked with statistically significant difference analysis: Student t test was used between two groups, One-way ANOVA analysis method was used for three groups or more, * indicates P < 0.05, ** indicates P < 0.01, *** indicates P < 0.001, and ns indicates no significant difference.

[0023] Figure 3 In the figure, A is the healthy group, i.e., the colon tissue of mice without any treatment; B is the Control group; C is the PI-IBS group; D is the HP-β-CD group; E is the SFN group; and F is the SFN inclusion compound group.

[0024] As used herein, the following words and phrases are generally intended to have the meanings set forth below, unless the context indicates otherwise.

[0025] The term "pharmaceutically acceptable" refers to a material that is not biologically or otherwise undesirable, for example, the material can be incorporated into a pharmaceutical preparation administered to a patient without causing any significant adverse biological effect or interacting with other components of the formulation in any harmful manner. Pharmaceutically acceptable excipients preferably meet the standards of toxicology and manufacturing testing.

[0026] A first aspect of the present invention provides a use of sulforaphane in the preparation of a medicament for treating and / or alleviating irritable bowel syndrome.

[0027] In a second aspect, the present invention provides a use of a sulforaphane inclusion compound in the preparation of a drug for treating and / or alleviating irritable bowel syndrome, wherein the sulforaphane inclusion compound comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives. The sulforaphane inclusion compound of the present invention effectively improves the stability of sulforaphane and increases the bioavailability of sulforaphane.

[0028] In the present invention, inclusion complex refers to an active ingredient (such as sulforaphane) encapsulated in an inclusion material.

[0029] The third aspect of the present invention provides a use of the sulforaphane or sulforaphane inclusion complex of the present invention in the preparation of a drug for treating and / or alleviating visceral hypersensitivity, wherein the sulforaphane and sulforaphane inclusion complex can effectively reduce visceral hypersensitivity, and the sulforaphane inclusion complex comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives.

[0030] In a fourth aspect, the present invention provides a use of the sulforaphane or sulforaphane inclusion complex of the present invention in the preparation of a medicament for regulating intestinal motility. The sulforaphane and sulforaphane inclusion complex can regulate intestinal motility. The sulforaphane inclusion complex comprises sulforaphane and an inclusion material, and the inclusion material is selected from cyclodextrin and its derivatives.

[0031] In a fifth aspect, the present invention provides a use of the sulforaphane or sulforaphane inclusion complex of the present invention in the preparation of a medicament for improving the intestinal barrier. The sulforaphane and sulforaphane inclusion complex can improve the intestinal barrier. The sulforaphane inclusion complex comprises sulforaphane and an inclusion material, and the inclusion material is selected from cyclodextrin and its derivatives.

[0032] In the present invention, the inclusion material is selected from cyclodextrin and its derivatives. The types of cyclodextrin and its derivatives can be selected from a wide range. This is an exemplary explanation, but it does not limit the scope of the present invention. According to a preferred embodiment of the present invention, it is selected from one or more of hydroxypropyl-β-cyclodextrin, 2,6-dimethyl-β-cyclodextrin, and sulfobutyl-β-cyclodextrin.

[0033] According to a preferred embodiment of the present invention, the inclusion material is hydroxypropyl-β-cyclodextrin, which can effectively improve the stability of sulforaphane and increase the bioavailability of sulforaphane.

[0034] In the present invention, the ratio of sulforaphane to inclusion material in the sulforaphane inclusion complex can be selected in a wide range, which is exemplary but not intended to limit the scope of the present invention. According to a preferred embodiment of the present invention, the mass ratio of sulforaphane to inclusion material is 1:4-12, for example, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10, 1:11, preferably 1:8-10. Within the above range, the stability of sulforaphane can be effectively improved and the bioavailability of sulforaphane can be increased.

[0035] In the present invention, the inclusion rate of sulforaphane in the sulforaphane inclusion complex can be selected in a wide range, which is exemplary but not intended to limit the scope of the present invention. According to a preferred embodiment of the present invention, at least 85% of sulforaphane is encapsulated in the inclusion complex, more preferably 86-95%, which can effectively improve the stability of sulforaphane and increase the bioavailability of sulforaphane.

[0036] Calculation method of inclusion rate: Centrifuge each sample of the inclusion solution at 12,000 rpm for 15 min, and take the supernatant for HPLC test to determine the content of unincluded drug in the inclusion solution. Inclusion rate = (total drug amount - unincluded drug amount) / total drug amount × 100%.

[0037] In the present invention, as long as sulforaphane can be encapsulated in the inclusion material, the inclusion method is not particularly limited, and any conventional inclusion method in the art may be used, such as a saturated aqueous solution method, a grinding method, or an ultrasonic method. For example, in the embodiment of the present invention, an ultrasonic method combined with magnetic stirring is used to include sulforaphane, but the scope of the present invention is not limited thereto.

[0038] According to a preferred embodiment of the present invention, the present invention provides a method for preparing the sulforaphane inclusion compound of the present invention, the method comprising:

[0039] (1) dissolving SFN in ethanol to obtain a 40-60 mg / mL SFN solution;

[0040] (2) dissolving the inclusion material in water to obtain a 34.8-52.2 mg / mL inclusion material solution;

[0041] (3) Under magnetic stirring conditions, the SFN solution and the inclusion material solution are mixed in a volume ratio of 1:8-12, ultrasonicated and stirred to obtain an SFN / inclusion material inclusion complex solution; and freeze-dried to obtain the sulforaphane inclusion complex.

[0042] In the present invention, the ultrasonic conditions are not particularly limited. According to a preferred embodiment of the present invention, the ultrasonic conditions include: the ultrasonic temperature is room temperature, the ultrasonic frequency is 20-40kHz, and the ultrasonic time can be adjusted according to actual needs, generally 5-15min.

[0043] In the present invention, the freeze-drying conditions are not particularly limited and may be any conventional conditions in the art. According to a preferred embodiment of the present invention, the inclusion compound solution is pre-frozen at -80°C for 4 hours and then freeze-dried for 24 hours to obtain sulforaphane inclusion compound powder.

[0044] In the present invention, the sulforaphane inclusion compound powder is stored at low temperature and away from light. According to a specific embodiment of the present invention, the storage condition is stored in a brown vial at 4°C.

[0045] In the present invention, the dosage range of the drug to exert its pharmacodynamic effect is relatively wide. According to a preferred embodiment of the present invention, the dosage of the drug to exert its pharmacodynamic effect is 5-100 mg / kg, preferably 40-60 mg / kg, calculated as sulforaphane. Within the above range, there is a significant improvement effect on visceral hypersensitivity, intestinal motility disorders and impaired intestinal barrier function. In the embodiments of the present invention, 50 mg / kg is used as an example to illustrate the advantages of the present invention, but the present invention is not limited thereto.

[0046] In the present invention, the types of irritable bowel syndrome (IBS) can be selected from a wide range. According to a preferred embodiment of the present invention, irritable bowel syndrome is selected from at least one of irritable bowel syndrome with constipation (IBS-C), diarrhea (IBS-D), mixed (IBS-M), undefined (IBS-U) and post-inflammatory or post-infectious irritable bowel syndrome (PI-IBS).

[0047] In the present invention, according to a preferred embodiment of the present invention, the drug uses sulforaphane as the only component that exerts its pharmacological effect.

[0048] In the present invention, according to a preferred embodiment of the present invention, the pharmaceutical preparation is selected from one or more of an oral preparation, an injection preparation, and a rectal preparation.

[0049] In the present invention, the drug further comprises at least one pharmaceutically acceptable excipient, and the excipient has a wide range of optional types. According to a preferred embodiment of the present invention, the excipient is selected from one or more of a filler, a disintegrant, a lubricant, and a solvent.

[0050] In the present invention, the filler is selected from one or more of starch, lactose, dextrin and sucrose.

[0051] In the present invention, the disintegrant is selected from one or more of starch, microcrystalline cellulose, carboxymethyl cellulose calcium, and cross-linked carboxymethyl cellulose sodium.

[0052] In the present invention, the lubricant is selected from one or more of magnesium stearate, talc, polyethylene glycol, and sodium lauryl sulfate.

[0053] In the present invention, in the pharmaceutical preparation, the types of solvents can be selected from a wide range, which is exemplary but not intended to limit the scope of the present invention. According to a preferred embodiment of the present invention, the solvent is selected from one or more of PBS and physiological saline.

[0054] In the present invention, there is no particular limitation on the dosage form of the drug, and the drug can be prepared into a corresponding dosage form according to the type of excipients, such as one or more of tablets, pills, powders, injections, and solutions.

[0055] In order to further understand the present invention, preferred embodiments of the present invention are described below in conjunction with the accompanying drawings and examples. However, it should be understood that these descriptions are only for further illustrating the features and advantages of the present invention, rather than limiting the claims of the present invention.

[0056] In the following examples, unless otherwise specified, all are conventional experimental methods; the experimental consumables used are from conventional distributors.

[0057] In the following examples, mice were provided by Jiangsu Huachuang Xinnuo Pharmaceutical Technology Co., Ltd., approved by the Animal Ethics Review Committee, and raised in the Experimental Animal Center of Gannan Medical University.

[0058] Preparation Example 1

[0059] The preparation of sulforaphane inclusion complex is as follows: Figure 1 As shown, the specific steps are as follows:

[0060] (1) Weigh an appropriate amount of SFN and dissolve it in ethanol to obtain a 50 mg / mL SFN solution;

[0061] (2) Weigh an appropriate amount of HP-β-CD and dissolve it in water to obtain a 43.5 mg / mL HP-β-CD solution;

[0062] (3) Under magnetic stirring conditions, the SFN solution was slowly added dropwise to the HP-β-CD solution at a volume ratio of 1:10, and the mixture was mixed by ultrasonication at 30 kHz for 5 min. The mixture was stirred at 800 rpm for 2 h to obtain a SFN / HP-β-CD inclusion complex solution with an inclusion rate of 89.2%.

[0063] (4) The inclusion complex solution was pre-frozen at -80°C for 4 h and then freeze-dried for 24 h to obtain SFN / HP-β-CD powder.

[0064] (5) The above SFN / HP-β-CD lyophilized powder was sealed in a brown vial at 4°C and reconstituted with physiological saline before use so that the concentration of SFN / HP-β-CD in the solution was 50 mg / mL based on SFN.

[0065] 1. Establishment of IBS animal model and drug intervention, such as Figure 2 shown.

[0066] (I) Experimental materials are as follows:

[0067] 1. Experimental animals:

[0068] C57BL6 / J mice aged 6-8 weeks, weighing 20-25 g, 15 mice in each group.

[0069] 2. Drugs:

[0070] Sulforaphane, hydroxypropyl-β-cyclodextrin (Solabo Technology Co., Ltd., C7070), carmine, FITC-D4000, etc. are all commercially available products.

[0071] 3. Other reagents / consumables / instruments

[0072] 75% ethanol, 4% paraformaldehyde, paraffin oil, normal saline, surgical instruments, urinary catheter (Fr 6, 2mm diameter), centrifuge tubes of various specifications, high-speed centrifuge, multi-function microplate reader, etc.

[0073] (II) Experimental plan

[0074] IBS mouse modeling: The mice were fasted for 12 hours in advance but not water. After anesthesia, 16 mg / mL TNBS-50% ethanol mixed solution was dripped into the colon at a dose of 80 mg / kg at 3.5 cm from the anus. The mice were placed on a warming pad with their heads tilted 45° downward for 15 minutes and then reset until awake. The control group was treated with 0.1 mL / 20 g PBS colon drip.

[0075] After 28 days of recovery, the mice were divided into groups for drug intervention as follows: Control group: control group, control group mice were gavaged with 0.2 mL / 20 g normal saline for 10 days; PI-IBS group: model group, IBS model mice were gavaged with 0.2 mL / 20 g normal saline for 10 days; SFN group: sulforaphane treatment group, IBS model mice were gavaged with 50 mg / kg SFN for 10 days; HP-β-CD group: hydroxypropyl-β-cyclodextrin treatment group, IBS model mice were gavaged with 435 mg / kg HP-β-CD for 10 days; SFN inclusion group: SFN / HP-β-CD (SFN-E) group, sulforaphane inclusion group, IBS model mice were gavaged with 10 mL / kg sulforaphane inclusion compound obtained in Preparation Example 1 for 10 days.

[0076] 2. HE staining of colon tissue

[0077] The colon tissues of mice in each group were fixed in 4% paraformaldehyde, embedded in paraffin and sliced, with a slice thickness of 5 μm. The slices were immersed in 56°C xylene for 20 minutes for dewaxing, and after dewaxing twice, they were hydrated with ethanol 4 times (twice 100%, once 95%, and once 75% ethanol) for 5 minutes each. Hematoxylin and eosin staining: the slices were immersed in 0.5% glacial acetic acid solution for 10 minutes, hematoxylin staining for 8 minutes, rinsed with tap water for 1 minute, differentiated with 1% hydrochloric acid ethanol for 5 seconds, observed the cell nucleus staining under a microscope, flow-through colorimetric analysis for 1 hour, immersed in 95% ethanol for 5 minutes, eosin staining for 1 minute, and rinsed with distilled water for 1 minute. The slices were placed in 95% ethanol and anhydrous ethanol twice, each for 3 minutes, transparent in xylene for 15 minutes twice, sealed with neutral gum, and examined under a microscope.

[0078] 3. Visceral Sensitivity Analysis Experiment

[0079] The mice were modeled by TNBS induction. After a 28-day recovery period, the visceral sensitivity was tested by abdominal withdrawal reflex (AWR) scoring. The test method is as follows: the mice were fasted for 12 hours in advance, anesthetized, and the uninflated dilatation balloon catheter (6-Fr, outer diameter 2mm) coated with paraffin oil was slowly inserted into the colon of the mouse, and the catheter was fixed to the tail of the mouse with medical tape; the colorectal dilatation test was performed after the mouse woke up and adapted for 45 minutes. The balloon pressure was increased to the specified level (0.15, 0.30, 0.45, 0.60mL) by inflating the syringe, and the expansion lasted for 20s, with a rest of 5min between each group. The pressure experiment at each level was repeated three times. During the expansion period, the abdominal withdrawal reflex phenomenon of the mouse was observed and recorded and scored. The scoring criteria are shown in Table 1.

[0080] Table 1 Mouse abdominal wall withdrawal reflex score table

[0081] Points Behavioral response 0 points No behavioral response to balloon inflation 1 point Occasional head movement 2 points Slight contraction of abdominal muscles 3 points Strong abdominal muscle contraction and abdominal wall lift 4 points Strong abdominal contraction, abdominal wall lift and body arching

[0082] 4. Intestinal motility test

[0083] Gastrointestinal motility was determined by evaluating the gastrointestinal transit (GI Transit) time and defecation frequency. Mice were given a 6% carmine solution at a dose of 10 μL / g by gavage, and were caged individually with a layer of white paper on the bottom of the cage for easy observation. They ate and drank normally. The mice were observed every 15 minutes, and the time when carmine appeared in the feces was recorded as the intestinal transit time of the mice.

[0084] 5. Intestinal Permeability Assessment

[0085] The intestinal permeability of mice was evaluated using fluorescein isothiocyanate-labeled dextran (FITC-D4000, molecule 3-5kD) as a molecular marker. FITC-D4000 was dissolved in sterile saline to prepare a 50mg / mL working solution, and then gavaged into mice at a dose of 600mg / kg; 2 hours after gavage, orbital blood was collected and the serum to be tested was separated. The blank serum of mice that were not gavaged with FITC-D4000 was used as the diluent, and the gavage working solution was gradiently diluted to prepare a standard curve.

[0086] Each serum sample was diluted 2-fold with normal saline, 100 μL was taken to a black ELISA plate, and the concentration of the marker in the serum was tested using a multifunctional ELISA reader (excitation wavelength 485 nm, emission wavelength 525 nm).

[0087] 6. Stability Assessment of Sulforaphane

[0088] The free SFN solution and SFN / HP-β-CD solution were sealed in a vial and placed in a 37°C thermostat away from light for one week. Samples were taken regularly (on the 0th, 1st, 2nd, 3rd, 5th, and 7th days) and the content was analyzed by HPLC. The analysis conditions were as follows: C18 column (5 μm, 150 mm × 4.6 mm, ), injection volume 20 μL, isocratic elution with mobile phase acetonitrile: water = 20:80, flow rate 1.0 mL / min, column temperature 35°C, detection wavelength 254 nm.

[0089] According to the SFN content, the residual rate R is calculated as SFN test concentration / SFN initial concentration*100%. The obtained residual rate R is taken logarithm and plotted against time to establish a linear fitting equation. Through the fitting equation, the time t value when the residual rate R is 0.9, i.e., T90, is calculated.

[0090] 7. Pharmacokinetic evaluation of drugs

[0091] SFN was dissolved in methanol to prepare a 0.5 mg / mL stock solution, which was diluted to 100 μL with an appropriate amount of blank plasma to prepare a gradient (10, 15, 20, 25, 50, 75 and 100 ng / mL) standard working solution. 100 μL of acetonitrile and 50 μL of methanol were added, vortexed for 30 s, centrifuged at 12000 rpm for 10 min, and the supernatant was taken for HPLC analysis.

[0092] The mice were fasted overnight and allowed free access to water. They were orally administered with 50 mg / kg of SFN and SFN / HP-β-CD (calculated as SFN). 250 μL of blood was collected from the tail vein into a heparinized tube at regular intervals (0.25, 0.5, 1, 1.5, 2, 4, 8, 12 and 24 hours) after administration. The blood was centrifuged at 3000 rpm for 10 minutes, and the supernatant was the plasma sample to be analyzed.

[0093] Phoenix WinNonlin 8.1.0 software was used to calculate the pharmacokinetic parameters: the terminal elimination rate constant (λ) was predicted by log-linear regression analysis of the terminal part of the SFN plasma concentration-time curve. z ). Terminal elimination half-life (t 1 / 2 ) Calculate using Keusing formula: t 1 / 2 =0.693 / λ z The maximum experimental plasma concentration (C max ) and the time required to reach this concentration (t max The area under the drug-time curve (AUC, ng / mL·h) was calculated according to the linear trapezoidal method until the last measurement point and was expressed by C Last / λ z Extrapolate it to infinity, where C Last is the final plasma sample concentration. Based on the AUC value obtained, the apparent systemic clearance (CI) = dose / AUC and the apparent distribution volume (V d ) = dose / λ z × AUC. According to the AUC value, calculate the relative bioavailability = AUC SFN-E *SFN-E dose / AUC SFN / SFN dose*100%.

[0094] VII. Experimental Results

[0095] 1. HE staining results

[0096] HE staining results Figure 3 As shown, the results showed that the colon of PI-IBS model mice had no obvious structural damage, no inflammatory cell infiltration, no pathological characteristics related to inflammatory bowel diseases such as ulcerative colitis (UC) and Crohn's disease (CD), which was consistent with the characteristics of functional bowel diseases such as IBS models, indicating that the model was successfully established. After drug intervention, no pathological changes occurred in colon tissue, indicating that the oral administration of a given dose of SFN, SFN inclusion complex and HP-β-CD had no obvious negative effects on the intestine.

[0097] 2. Results of visceral hypersensitivity reactions in mice treated with different methods

[0098] (1) TNBS-induced modeling. After a 28-day recovery period, the visceral sensitivity of mice in the control and model groups was evaluated by abdominal withdrawal reflex scores. The results were as follows: Figure 4 shown.

[0099] At the 0.15mL expansion level, the score of the Control group was 0.50±0.18, and the score of the PI-IBS group was 1.11±0.27, with a significant difference (P<0.001); at the 0.30mL expansion level, the score of the Control group was 0.89±0.17, and the score of the PI-IBS group was 2.72±0.39, with an extremely significant difference (P<0.0001); at the 0.45mL expansion level, the score of the Control group was 2.56±0.50, and the score of the PI-IBS group was 3.39±0.49, showing a significant difference (P<0.05); at the 0.60mL expansion level, the score of the PI-IBS group was slightly higher than that of the Control group, but there was no significant difference. The above results suggest that the model mice have visceral hypersensitivity, which together with the HE results verify the successful establishment of the mouse IBS model.

[0100] (2) After 10 days of drug intervention, the visceral sensitivity of each group of mice was evaluated by abdominal withdrawal reflex scores. Figure 5 shown.

[0101] Figure 5 A results showed that at the 0.15mL expansion level, the average score of the Control group was 0.56, the PI-IBS group scored 1.22, the HP-β-CD group scored 1.33, the SFN group scored 0.89, and the SFN inclusion group scored 0.78; compared with the Control group, the score of the PI-IBS group was significantly higher (P<0.05);

[0102] After SFN drug treatment, the abdominal withdrawal reflex score of mice was significantly decreased (P<0.05), indicating that SFN can effectively improve the visceral hypersensitivity of mice with irritable bowel syndrome; after SFN inclusion drug treatment, the abdominal withdrawal reflex score of mice in the SFN inclusion group was significantly decreased compared with the PI-IBS group (P<0.05), indicating that SFN inclusion can effectively improve the visceral hypersensitivity of mice with irritable bowel syndrome, and the score of the SFN inclusion group was lower than that of the SFN group.

[0103] Figure 5B The results showed that at the 0.30mL expansion level, the average score of the Control group was 0.89, the score of the PI-IBS group was 2.56, the score of the HP-β-CD group was 2.67, the score of the SFN group was 1.78, and the score of the SFN inclusion group was 1.44; compared with the Control group, the score of the PI-IBS group was significantly increased (P<0.001); after SFN drug treatment, the abdominal withdrawal reflex score of the mice was significantly decreased (P<0.05), indicating that SFN can effectively improve the visceral hypersensitivity of mice with irritable bowel syndrome. After SFN inclusion drug treatment, the abdominal withdrawal reflex score of the SFN inclusion group mice was significantly decreased compared with the PI-IBS group (P<0.01), and the score of the SFN inclusion group was lower than that of the SFN group, indicating that the SFN inclusion of the present invention can further improve the visceral hypersensitivity of mice with irritable bowel syndrome.

[0104] Figure 5 C The results showed that at the 0.45 mL expansion level, the average score of the Control group was 2.11, the score of the PI-IBS group was 3.33, the score of the HP-β-CD group was 3.22, the score of the SFN group was 2.67, and the score of the SFN inclusion compound group was 2.3; compared with the Control group, the score of the PI-IBS group was significantly increased (P<0.05); after SFN drug treatment, the abdominal withdrawal reflex score of SFN mice was downregulated, but no statistical difference was observed (P>0.05), indicating that SFN can improve the visceral hypersensitivity of irritable bowel syndrome mice. After SFN inclusion compound drug treatment, the score of the SFN inclusion compound group was significantly downregulated compared with the PI-IBS group (P<0.05), indicating that the SFN inclusion compound of the present invention can more effectively improve the visceral hypersensitivity of irritable bowel syndrome mice.

[0105] Figure 5 D The results showed that at the 0.60 mL distension level, the abdominal withdrawal reflex of mice in each group was strong, with scores close to 4.0, and there was no significant difference among the groups (P>0.05).

[0106] The above results showed that the abdominal withdrawal reflex scores of the PI-IBS group at the 0.15-0.45 mL distension level were significantly higher than those of the Control group, indicating that visceral sensitivity increased after modeling. HP-β-CD intervention alone had no significant effect. After drug intervention in the SFN group, the abdominal withdrawal reflex score was lower than that in the Control group, effectively reducing visceral hypersensitivity. In addition, the abdominal withdrawal reflex score of the SFN inclusion compound group was more significantly reduced after drug intervention, and the improvement effect of visceral hypersensitivity was more significant.

[0107] 3. Results of intestinal motility regulation in mice treated with different methods

[0108] The intestinal motility of mice was tested by the pigment carmine excretion method. Figure 6 shown.

[0109] The average gastrointestinal transit time of the Control group was 178.4 min, and the average transit time of the PI-IBS group was 87.3 min; the average transit time of the HP-β-CD group was 93.8 min, which was not significantly different from the PI-IBS group; the average transit time of the SFN group was 146.2 min, and the average transit time of the SFN inclusion group was 165.0 min; compared with the Control group, the average transit time of mice in the PI-IBS group was significantly decreased (P<0.01); after SFN drug treatment, the average transit time of mice was significantly increased (P<0.05), and after drug treatment in the SFN inclusion group, the average transit time of mice was more significantly increased than that in the SFN group (P<0.01). The above results suggest that the PI-IBS model mice have faster defecation frequency and the intestinal transit time of pigments is significantly lower than that of normal mice. There is no significant improvement with HP-β-CD intervention alone, and there is no statistical difference in the intestinal transit time of pigments compared with the PI-IBS group. After SFN intervention, the defecation frequency of mice decreased and the gastrointestinal transit time increased significantly, indicating that SFN has an intestinal motility regulating effect; and the effect of SFN inclusion complexes in regulating intestinal motility is more obvious, and its intestinal transit speed after intervention is close to that of the Control group.

[0110] 4. Results of improvement in intestinal barrier in mice treated with different methods

[0111] After mice were intragastrically treated with FITC-D4000-dextran marker, the marker concentration in their serum was tested to evaluate intestinal permeability. Figure 7 shown.

[0112] The average concentration of the marker in the Control group was 1.02μg / mL, the average concentration in the PI-IBS group was 1.51μg / mL, the average concentration in the HP-β-CD group was 1.54μg / mL, the average concentration in the SFN group was 1.25μg / mL, and the average concentration in the SFN inclusion group was 1.15μg / mL; compared with the Control group, the concentration of the marker in the serum of mice in the PI-IBS group was significantly increased (P<0.0001); after SFN drug treatment, the concentration of the marker in the serum of mice was significantly decreased (P<0.01), and the concentration of the marker in the SFN inclusion group after drug treatment was lower than that in the SFN group. The above results showed that the intestinal leakage of fluorescent markers in the PI-IBS group mice was significantly higher than that in normal mice, indicating that the permeability of the intestinal barrier of mice increased; after SFN intervention, the leakage was significantly reduced, and the permeability of the intestinal barrier was restored; and the leakage was further reduced after SFN inclusion complex intervention, while HP-β-CD intervention alone had no obvious effect, indicating that SFN inclusion complex can more effectively improve the permeability of the intestinal barrier of mice.

[0113] 5. Stability assessment of sulforaphane

[0114] The stability of SFN was evaluated at 37°C for 7 days. The results are shown in Table 2 and Figure 8 The linear fitting equation of free SFN is log(R)=-0.0324t+2.0154. When R is 0.9, T90 is only 0.18 days. After 7 days, SFN still has 16.60% of the initial concentration, indicating that the stability of free SFN is poor. The linear fitting equation of SFN after HP-β-CD inclusion is log(R)=-0.1153t+1.975, T90 is extended to 1.89 days. After 7 days, SFN still has 60.26% of the initial concentration. The results show that the stability of SFN is significantly improved after HP-β-CD inclusion (P<0.01).

[0115]

[0116] Table 2 Stability evaluation table of sulforaphane

[0117] 6. Pharmacokinetic evaluation of sulforaphane

[0118] After mice were given a single dose of SFN solution and SFN-E inclusion complex orally, the SFN drug concentration in plasma was measured at regular intervals. The blood drug concentration-time curves were as follows: Fig. 9 Phoenix WinNonlin software was used to fit and calculate the main pharmacokinetic parameters of SFN (see Table 3). The results showed that free SFN was rapidly absorbed after oral administration, reaching a maximum plasma concentration of 32.183±2.216 ng / mL at 0.5 h, followed by rapid distribution and metabolism, with a half-life of 6.864±1.153 h; while the SFN inclusion group reached a maximum plasma concentration of 68.360±6.312 ng / mL at 2 h, which was approximately twice that of the SFN group, and the half-life was significantly prolonged to 10.281±2.238 h (vs SFN group, P<0.05). In addition, compared with the SFN group, the apparent clearance and apparent distribution volume of the SFN inclusion group were significantly reduced (P<0.01), and AUC 0-t , AUC 0-inf The relative bioavailability is significantly improved by 3.325 times.

[0119] Table 3 Pharmacokinetic evaluation results

[0120] Pharmacokinetic parameters SFN SFN-E <![CDATA[AUC 0-t (mg / mL)]]> 188.864±16.852 628.049±43.263** <![CDATA[AUC 0-inf (mg / mL)]]> 215.375±12.827 764.746±67.138* <![CDATA[C max (ng / mL)]]> 32.183±2.216 68.360±6.312* <![CDATA[T max (h)]]> 0.5 2.0 <![CDATA[λ z (1 / h)]]> 0.101±0.012 0.067±0.015* <![CDATA[t 1 / 2 (h)]]> 6.864±1.153 10.281±2.238* <![CDATA[V d (L / kg)]]> 2298.829±286.492 969.709±168.347*** CI(L / h / Kg) 232.153±43.295 65.381±5.926***

[0121] Note: SFN-E vs SFN, * means P < 0.05, ** means P < 0.01, *** means P < 0.001.

[0122] 7. Experimental conclusion

[0123] 1. SFN can reduce visceral sensitivity, especially at the balloon expansion level of 0.30mL. SFN inclusion complex is more effective in reducing visceral sensitivity. SFN inclusion complex improves visceral sensitivity at all expansion levels, especially at 0.15mL and 0.30mL expansion levels. Due to the improved stability and bioavailability of sulforaphane in SFN inclusion complex, it provides greater application potential for the treatment of functional bowel disorders. At the 0.60mL expansion level, there was no significant difference in the visceral sensitivity scores of the groups, suggesting that under high expansion pressure, visceral sensitivity regulation may reach the physiological limit.

[0124] 2. The intestinal transit time of PI-IBS model mice was significantly lower than that of normal mice, and the transit speed was significantly increased. After SFN intervention, the gastrointestinal transit time of mice increased significantly, and the transit speed slowed down, indicating that SFN can effectively regulate intestinal motility. After SFN inclusion drug intervention, the gastrointestinal transit time of mice increased significantly, indicating that the effect of SFN inclusion compound in regulating intestinal motility was more obvious.

[0125] 3. The intestinal permeability of PI-IBS model mice was significantly increased compared with that of normal mice. After intervention with SFN inclusion complex, the intestinal permeability of mice was reduced and the intestinal barrier was improved. After treatment with SFN inclusion complex, the intestinal permeability of mice was further reduced and the treatment effect was better, indicating that the intestinal barrier can be effectively improved.

[0126] 4. The thermal stability of SFN inclusion complex at 37°C is significantly improved compared with SFN, and T90 is significantly prolonged.

[0127] 5. SFN inclusion complex significantly affects the absorption and distribution of SFN in the body, has different degrees of influence on the main pharmacokinetic parameters, and significantly improves the relative bioavailability.

[0128] The above results show that SFN has effective effects in relieving visceral hypersensitivity, regulating intestinal motility and improving intestinal barrier. After SFN is encapsulated by HP-β-CD, its stability and bioavailability are improved, which not only further enhances the drug effect, but also effectively reduces the cost of medication, which is of great significance for the treatment of functional bowel diseases.

[0129] The preferred embodiments of the present invention are described in detail above, but the present invention is not limited thereto. Within the technical concept of the present invention, the technical solution of the present invention can be subjected to a variety of simple modifications, including the combination of various technical features in any other suitable manner, and these simple modifications and combinations should also be regarded as the contents disclosed by the present invention and belong to the protection scope of the present invention.

Claims

1. Use of sulforaphane in the preparation of a drug for treating and / or alleviating irritable bowel syndrome.

2. Use of a sulforaphane inclusion complex in the preparation of a drug for treating and / or alleviating irritable bowel syndrome, wherein the sulforaphane inclusion complex comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives.

3. Use of sulforaphane and / or sulforaphane inclusion complex in the preparation of a drug for treating and / or alleviating visceral hypersensitivity, wherein the sulforaphane inclusion complex comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives.

4. Use of sulforaphane and / or sulforaphane inclusion complex in the preparation of a drug for regulating intestinal motility, wherein the sulforaphane inclusion complex comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives.

5. Use of sulforaphane and / or sulforaphane inclusion complex in the preparation of a drug for improving intestinal barrier, wherein the sulforaphane inclusion complex comprises sulforaphane and an inclusion material, wherein the inclusion material is selected from cyclodextrin and its derivatives.

6. The use according to any one of claims 2 to 5, wherein: The inclusion material is selected from one or more of hydroxypropyl-β-cyclodextrin, 2,6-dimethyl-β-cyclodextrin, and sulfobutyl-β-cyclodextrin; preferably hydroxypropyl-β-cyclodextrin.

7. The use according to any one of claims 2 to 6, wherein: In the sulforaphane inclusion complex, the mass ratio of sulforaphane to inclusion material is 1:4-12, preferably 1:8-10.

8. The use according to any one of claims 2 to 6, wherein: At least 85% of the sulforaphane is encapsulated in the inclusion complex, preferably 86-95%.

9. The use according to any one of claims 1 to 6, wherein: The irritable bowel syndrome is selected from at least one of constipation-type, diarrhea-type, mixed-type, amorphous-type and post-inflammatory or post-infectious irritable bowel syndrome.

10. The use according to any one of claims 1 to 6, wherein: The drug further comprises at least one pharmaceutically acceptable excipient selected from one or more of a filler, a disintegrant, a lubricant, and a solvent.